BARDA
Numerous technologies in development to help with the diagnosis of sepsis have a singular objective ─ detect the condition as quickly as possible.
Becton Dickinson, BARDA Ink $40.3M Contract for Five Combo Assays
The tests could be used to make treatment and management decisions, and inform on epidemiologic trends or new and emerging viruses.
BARDA Awards $733K to AAD to Develop Rapid Analyzer For Early Detection of Severe Infection
The firm said its system is being developed to deliver laboratory-grade results in two minutes and for use in urgent care clinics, doctors' offices, and other settings.
BARDA Exercises $6.4M Option on T2 Biosystems Contract
The funding supports development of antimicrobial resistance, biothreat agent, and sepsis pathogen panels, as well as a next-gen instrument.
OraSure Technologies Nabs $13.6M BARDA Funding
The funding will support OraSure's efforts to obtain 510(k) clearance and CLIA waiver for the InteliSwab rapid SARS-CoV-2 antigen test.
Jul 30, 2021
Cepheid Gets $28M From BARDA for SARS-CoV-2 Tests
May 6, 2021
T2 Biosystems Q1 Revenues Nearly Triple
Apr 26, 2021
Sep 30, 2020